Clinical evaluation of biomarkers in Gaucher disease.
Novel or candidate biomarkers require thorough evaluation to establish their utility in a clinical setting. This paper describes an evaluation of several established enzyme markers of Gaucher disease and a newly-described chemokine, pulmonary and activation-regulated chemokine (PARC). The ability of the biomarkers to rank patients with Gaucher disease in order of disease severity and organ bulk, and to reflect changes in key clinical parameters in response to enzyme replacement therapy were evaluated. PARC concentrations were found to be reliably correlated with visceral disease and with key clinical responses to enzyme replacement in an unbiased manner. Unlike chitotriosidase and serum angiotensin-converting enzyme activity, genetic variation in serum PARC did not appear to influence its utility as a biomarker.


CONCLUSIONS
For each new candidate biomarker of lysosomal storage diseases, a similar clinical evaluation will be required, though the approach will need to be modified according to the clinical features and natural history of each disorder.
Deegan
P B
PB
Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. pbd21@medschl.cam.ac.uk
Cox
T M
TM
D000135:Acid Phosphatase / Q000378:metabolism*; D015415:Biomarkers; D019742:Chemokines, CC / Q000235:genetics*; D005776:Gaucher Disease / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D006596:Hexosaminidases / Q000378:metabolism*; D006801:Humans; D010976:Platelet Count; D013154:Spleen / Q000002:abnormalities
D015415:Biomarkers; C111792:CCL18 protein, human; D019742:Chemokines, CC; D000135:Acid Phosphatase; D006596:Hexosaminidases; C086400:chitotriosidase